Covovax distributor inks deal with Unilab for private sector access to COVID-19 vaccine

enablePagination: false
maxItemsPerPage: 10
totalITemsFound:
maxPaginationLinks: 10
maxPossiblePages:
startIndex:
endIndex:

Metro Manila (CNN Philippines, January 23) — Faberco Life Sciences, Inc., the distributor of the Covovax vaccine in the country, and Unilab, Inc. signed an agreement to make the said COVID-19 vaccine available to workers of the private sector.

In a statement, Unilab said this will also be subject to the approval of the National Task Force Against COVID-19, the Department of Health, and the Food and Drug Administration’s decision on its application for emergency use authorization.

The regulator has so far issued EUA to the Pfizer-BioNTech vaccine, while applications of AstraZeneca, Sinovac, and Gamaleya are pending.

Under the agreement, Faberco appointed Unilab as its authorized partner for the distribution of the US-developed vaccine to the private sector.

“We are prepared to help the Philippine government in protecting the people by enabling more access to COVID-19 vaccines through the private sector,” Faberco founder Kishore Hemlani said.

Atty. Jose Maria Ochave, senior vice president for Social Partnerships of Unilab, said the vaccines will be made available especially to essential industries at no cost to their employees. Depending on the company’s financial capability, families of their employees and their selected communities may also be given access to the vaccine.

“Further, the distribution and administration of the vaccine will be strictly subject to the guidelines set forth by the Department of Health, including those pertaining to pharmacovigilance,” he added.

Faberco is also the partner of Serum Institute of India in the Philippines. They recently signed a term sheet with the Philippine government for 30 million doses of Covovax.

The government targets to procure 148 million doses of COVID-19 vaccine to inoculate up to 70 million Filipinos this year.